Boston Scientific Announces Schedule for European Society of Cardiology Con...( NATICK Mass. Aug. 29 /- Boston Sc...),Health

NATICK, Mass., Aug. 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the European Society of Cardiology Congress 2007, which runs from September 1 to 5 in Vienna, Austria.

The Company plans to announce five-year results from the TAXUS II clinical trial. The data are expected to build on the strong body of clinical evidence supporting the continued efficacy and long-term safety profile of the TAXUS(R) Paclitaxel-Eluting Stent System. In addition, the Company will announce partial one-year data from Phases II and III of the OLYMPIA registry, designed to study real-world outcomes of its TAXUS(R) Liberte(TM) Paclitaxel-Eluting Stent System. The Company anticipates the data will further reinforce the safety and efficacy of its second-generation drug-eluting stent system.

Details of the Company's activities at ESC 2007 are below.

Schedule of events (all times are Vienna time)

Sunday, September 2

-- OLYMPIA Phase II & III one-year data. Preliminary results from Phases

II & III of the global OLYMPIA registry will be presented by Martyn

Thomas, M.D., F.R.C.P., at 4:45 p.m., in the Helsinki Room (Zone 2).

OLYMPIA is a prospective, multi-center, multi-phased registry with a

planned enrollment of up to 27,000 patients, making it the largest

study of its kind worldwide. The registry is designed to analyze real-

world clinical outcomes data for Boston Scientific's second-generation

TAXUS Liberte Paclitaxel-Eluting Stent System. Results from more than

7,000 Phase II and III patients will focus on safety and efficacy, and<
'/>"/>